Pharmaids Pharmaceuticals Ltd
Incorporated in 1989, Pharmaids Pharmaceuticals Ltd operates in research, development, and manufacturing services.
It is undergoing a business transition and aims to build a CRDMO platform.[1]
- Market Cap ₹ 114 Cr.
- Current Price ₹ 32.2
- High / Low ₹ 66.0 / 25.6
- Stock P/E
- Book Value ₹ 15.1
- Dividend Yield 0.00 %
- ROCE -15.8 %
- ROE -23.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 33.0%
- Company has a low return on equity of -14.9% over last 3 years.
- Debtor days have increased from 36.2 to 47.5 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.73 | 1.68 | 1.20 | 0.45 | 0.56 | 0.00 | 8.55 | 3.94 | 0.00 | 0.03 | 2.34 | 10.60 | 9.49 | |
| 1.82 | 2.03 | 1.54 | 0.84 | 0.67 | 0.34 | 8.45 | 3.81 | 9.89 | 6.41 | 9.60 | 24.80 | 19.70 | |
| Operating Profit | -0.09 | -0.35 | -0.34 | -0.39 | -0.11 | -0.34 | 0.10 | 0.13 | -9.89 | -6.38 | -7.26 | -14.20 | -10.21 |
| OPM % | -5.20% | -20.83% | -28.33% | -86.67% | -19.64% | 1.17% | 3.30% | -21,266.67% | -310.26% | -133.96% | -107.59% | ||
| 0.12 | 0.05 | 0.53 | 0.02 | 0.01 | 0.00 | 0.03 | 0.02 | 0.00 | 0.80 | 1.02 | 3.77 | 7.67 | |
| Interest | 0.00 | 0.03 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | 2.15 | 3.31 | 2.76 |
| Depreciation | 0.14 | 0.10 | 0.06 | 0.00 | 0.05 | 0.04 | 0.04 | 0.01 | 0.02 | 0.18 | 0.20 | 0.21 | 0.22 |
| Profit before tax | -0.11 | -0.43 | 0.09 | -0.37 | -0.15 | -0.38 | 0.09 | 0.14 | -9.91 | -6.09 | -8.59 | -13.95 | -5.52 |
| Tax % | -36.36% | -6.98% | -33.33% | 5.41% | 20.00% | -107.89% | 0.00% | 0.00% | -23.71% | -18.72% | -15.25% | -25.23% | |
| -0.07 | -0.40 | 0.11 | -0.39 | -0.18 | 0.03 | 0.09 | 0.15 | -7.56 | -4.95 | -7.28 | -10.44 | -3.94 | |
| EPS in Rs | -0.21 | -1.17 | 0.32 | -1.15 | -0.53 | 0.03 | 0.09 | 0.15 | -3.52 | -1.40 | -2.06 | -2.96 | -1.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 4% |
| 3 Years: | % |
| TTM: | 188% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -41% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 20% |
| 3 Years: | -8% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | -15% |
| 5 Years: | -17% |
| 3 Years: | -15% |
| Last Year: | -23% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.36 | 3.36 | 3.36 | 3.36 | 10.27 | 10.27 | 10.27 | 10.27 | 21.44 | 35.27 | 35.27 | 35.27 |
| Reserves | -1.65 | -2.05 | -1.94 | -2.32 | -1.87 | -1.84 | -1.74 | -1.60 | 0.98 | 35.79 | 28.52 | 18.11 |
| 0.30 | 0.48 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.93 | 35.74 | 20.63 | |
| 0.51 | 0.51 | 0.60 | 0.26 | 0.27 | 0.03 | 0.59 | 2.44 | 2.14 | 1.00 | 15.19 | 9.95 | |
| Total Liabilities | 2.52 | 2.30 | 2.02 | 1.30 | 8.67 | 8.46 | 9.12 | 11.11 | 24.56 | 84.99 | 114.72 | 83.96 |
| 0.46 | 0.44 | 0.00 | 0.00 | 0.08 | 0.08 | 0.04 | 0.03 | 0.11 | 16.55 | 24.18 | 8.05 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.45 | 0.45 | 0.45 | 2.00 | 2.30 | 3.51 | 5.47 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.27 | 52.60 | 52.61 | 52.54 |
| 2.06 | 1.86 | 2.02 | 1.30 | 8.14 | 7.93 | 8.63 | 10.63 | 19.18 | 13.54 | 34.42 | 17.90 | |
| Total Assets | 2.52 | 2.30 | 2.02 | 1.30 | 8.67 | 8.46 | 9.12 | 11.11 | 24.56 | 84.99 | 114.72 | 83.96 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.21 | 0.02 | 0.33 | -0.21 | -0.10 | -0.75 | 0.41 | -0.26 | -4.02 | -3.44 | -7.72 | -3.53 | |
| -0.01 | -0.08 | 0.33 | -0.09 | 0.00 | 0.66 | -0.23 | 0.47 | -4.95 | -72.51 | -18.90 | 24.53 | |
| -0.13 | 0.05 | -0.22 | -0.07 | -0.03 | 0.00 | 0.00 | 0.00 | 21.31 | 65.66 | 24.64 | -21.36 | |
| Net Cash Flow | 0.06 | -0.01 | 0.43 | -0.37 | -0.13 | -0.09 | 0.18 | 0.21 | 12.35 | -10.29 | -1.99 | -0.36 |
| Free Cash Flow | 0.20 | -0.06 | 0.70 | -0.21 | -0.12 | -0.79 | 0.41 | -0.26 | -5.69 | -19.81 | -16.76 | 13.57 |
| CFO/OP | -233% | -6% | -97% | 49% | 91% | 221% | 410% | -200% | 41% | 54% | 106% | 25% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 234.19 | 232.47 | 240.29 | 421.78 | 580.09 | 11.95 | 124.14 | 0.00 | 24.96 | 47.52 | ||
| Inventory Days | 102.77 | 91.25 | 130.75 | 0.00 | 0.00 | 16.55 | 90.99 | 0.00 | 4,197.50 | 1,774.15 | 0.00 | |
| Days Payable | 145.29 | 138.45 | 245.15 | 22.37 | 236.18 | 0.00 | 2,066.52 | |||||
| Cash Conversion Cycle | 191.67 | 185.27 | 125.89 | 421.78 | 580.09 | 6.14 | -21.05 | 4,197.50 | -267.41 | 47.52 | ||
| Working Capital Days | 181.45 | 147.74 | 161.21 | 227.11 | 2,652.77 | 2.99 | -17.60 | 14,600.00 | -471.07 | -342.27 | ||
| ROCE % | -5.26% | -21.05% | -24.30% | -30.08% | -3.18% | -4.52% | 1.06% | 1.63% | -63.75% | -10.83% | -7.02% | -15.85% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of Subsidiaries count |
|
||||||||
| Number of Permanent Employees count |
|||||||||
| Consolidated Revenue Mix - Job Work % of consolidated revenue |
|||||||||
| Consolidated Revenue Mix - Sale of Products % of consolidated revenue |
|||||||||
| Consolidated Revenue Mix - Sale of Services % of consolidated revenue |
|||||||||
| Subsidiary Revenue Share of Group Revenue % of consolidated revenue |
|||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Enclosed copies of Newspaper Advertisement published on August 19, 2026 intimating the Notice of 37th Annual General Meeting of the Company
-
Reg. 34 (1) Annual Report.
- 37th AGM on 11 Sep 2026; FY26 annual report filed, with board and financial updates.
- Notice Of 37Th Annual General Meeting And Annual Report
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper publication of unaudited financial results (standalone & consolidated) for the quarter ended June 30, 2026
-
Submission Of Unaudited Financial Results For The Quarter Ended June 30, 2026
- Board approved unaudited results for quarter ended June 30, 2026 and AGM notice.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1]
PPL is a fully integrated provider of Custom Research and Manufacturing Services (CRAMS) to various pharma and related companies.